Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment

Transfusion and Apheresis Science

Volumn 39, Issue 1, 2008, Pages 59-67

  Svae, Tor Einar ^a   Neisser Svae, Andrea ^a   Bailey, Andrew ^b   Reichl, Herwig ^c   Biesert, Lothar ^d   Schmidt, Torben ^d   Heger, Andrea ^a   Römisch, Jürgen ^a  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

^b ViruSure GmbH   (Austria)

^c Hämosan LSS GmbH   (Austria)

^d Virus and Prion Validation Department   (Germany)

Author keywords

FVIII; IVIG; Plasma; Prion safety; Solvent detergent; Transfusion; vCJD

Indexed keywords

ALBUMIN; ALBUMINATIV; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; GAMMANORM; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; OCTALBIN; OCTANATE; OCTANINE F; OCTAPLAS; OCTAPLEX; PROTHROMBIN COMPLEX; RHESONATIV; RHESUS D ANTIBODY; VON WILLEBRAND FACTOR; WILATE;

ARTICLE; BIOSAFETY; CREUTZFELDT JAKOB DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION PREVENTION; INFECTION RISK; PLASMA TRANSFUSION; PRION; VIRUS TRANSMISSION;

ANIMALS; BLOOD COMPONENT REMOVAL; BLOOD COMPONENT TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; CRICETINAE; DISINFECTION; HUMANS; PRPSC PROTEINS; SAFETY;

EID: 47349084677     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2008.05.006     Document Type: Article

References (50)

1. Yap P.L., Leaver H.A., and Gillon J. Prions: properties, occurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Vox Sang 74 Suppl. 2 (1998) 131-134
2. Hewitt P.E., Llewelyn C.A., Mackenzie J., et al. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 91 (2006) 221-230
3. Llewelyn C.A., Hewitt P.E., Knight R.S.G., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 (2004) 417-421
4. Wroe S.J., Pal S., Siddique D., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368 (2006) 2061-2067
5. Peden A.H., Head M.W., Ritchie D.L., et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 264 (2004) 527-529
6. Hilton D.A., Fathers E., Edwards P., et al. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 352 (1998) 703-704
7. Hill A.F., Butterworth R.J., Joiner S., et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353 (1999) 183-189
8. Smith P.G. The epidemics of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: current status and future prospects. Bull World Health Organ 81 (2003) 123-130
9. Andrews N.J., Farrington C.P., Ward H.J.T., et al. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet 361 (2003) 751-752
10. Norfolk D.R., Glaser A., Kinsey S., et al. American fresh frozen plasma for neonates and children. Arch Dis Child 90 (2005) 89-91
11. Sachse C., and Greinacher A. Relevance of Creutzfeldt-Jakob disease and its variant for transfusion medicine. Transfus Med Hemother 30 (2003) 179-185
12. Brown P., Rohwer R.G., Dunstan B.C., et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathies. Transfusion 38 (1998) 810-816
13. Cervenakova L., Yakovleva O., Mc Kenzie C., et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 43 (2003) 1687-1694
14. Bons N., Lehmann S., Mestre-Francès N., et al. Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion 42 (2002) 513-516
15. Hunter N., Foster J., Chong A., et al. Transmission of prion diseases by blood transfusion. J Gen Virol 83 (2002) 2897-2905
16. Prowse C.V., Hornsey V.S., Drummond O., et al. Preliminary assessment of whole-blood, red-cell and platelet-leucodepleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing. Br J Haematol 106 (1999) 240-247
17. Williamson L.M. New-variant Creutzfeldt-Jakob disease and leukocyte depletion of blood components. Infus Ther Transfus Med 26 Suppl. 2 (1999) 24-30
18. Gregori L., McCombie N., Palmer D., et al. Effectiveness of leukoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 364 (2004) 529-531
19. Wadsworth J.D.F., Joiner F., Hill A.F., et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358 (2001) 171-180
20. Bruce M.E., McDonnel I., Will R.G., et al. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 358 (2001) 208-209
21. Minor P.D. Technical aspects of the development and validation of tests for variant Creutzfeldt-Jakob disease in blood transfusion. Vox Sang 86 (2004) 164-170
22. Brown P. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. Vox Sang 89 (2005) 63-70
23. Rutala W.A., and Weber D.J. Creutzfeldt-Jakob disease: recommendations for disinfection and sterilisation. Clin Infect Dis 32 (2001) 1348-1356
24. Foster P.R. Removal of TSE agents from blood products. Vox Sang 87 Suppl. 2 (2004) S7-S10
25. Klohn P.C., Stoltze L., Flechsig E., et al. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci USA 100 (2003) 11666-11671
26. Dealler S. A matter for debate: the risk of bovine spongiform encephalopathy to humans posed by blood transfusion in the UK. Transfus Med 6 (1996) 217-222
27. Hilton D.A., Ghani A.C., Conyers L., et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 203 (2004) 733-739
28. Ironside J.W., Bishop M.T., Connolly K., et al. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 332 (2006) 1186-1188
29. Lee D.C., Stenland C.J., Hartwell R.C., et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Meth 84 (2000) 77-89
30. Stenland C.J., Lee D.C., Brown P., et al. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 42 (2002) 1497-1500
31. EMEA/CPMP/BWP/2879/02/rev 1. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. June 2004.
32. CPMP/ICH/295/95. Note for guidance on quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. March 1997.
33. Brown P., Cervenáková L., McShane L.M., et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 39 (1999) 1169-1178
34. Jaquemot C., Cuche C., Dormont D., et al. High incidence of scrapie induced by repeated injections of subinfectious prion doses. J Virol 79 (2005) 8904-8908
35. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. The Brit Soc Haematol 2004; 126:11-28.
36. Donnelly C.A., Ferguson N.M., Ghani A.C., et al. Implications of BSE infection screening data for the scale of the British BSE epidemic and current European infection levels. Proc R Soc Lond B 269 (2002) 2179-2190
37. Boelle P.Y., Thomas G., Valleron A.J., et al. Modelling the epidemic of variant Creutzfeldt-Jakob disease in the UK based on age characteristics: updated, detailed analysis. Stat Methods Med Res 12 (2003) 221-223
38. Foster P.R., Welch A.G., McLean C., et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 78 (2000) 86-95
39. Lee D.C., Stenland C.J., Miller J.L.C., et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 41 (2001) 449-455
40. Vey M., Baron H., Weimer T., et al. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 30 (2002) 187-196
41. Gregori L., Maring J.-A., MacAuley C., et al. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 32 (2004) 1-10
42. Foster P.R., Griffin B.D., Bienek C., et al. Distribution of bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang 86 (2004) 92-99
43. Thyer J., Unal A., Thomas P., et al. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins. Vox Sang 91 (2006) 292-300
44. Reichl H.E., Foster P.R., Welch A.G., et al. Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang 83 (2002) 137-145
45. Van Holten R.W., and Autenrieth S.M. Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang 85 (2003) 20-24
46. Tateishi J., Kitamoto T., Ishikawa G., et al. Removal of causative agent of Creutzfeldt-Jakob disease (CJD) through membrane filtration method. Membrane 18 (1993) 357-362
47. Brown P. Variant CJD transmission through blood: risks to predictors and "predictees". Transfusion 43 (2003) 425-427
48. Palo R., Capraro L., Hovilehto S., et al. Population-based audit of fresh-frozen plasma transfusion practices. Transfusion 46 (2006) 1921-1925
49. Lutze G., and Hartung K.J. Blood clotting factors. Determination of activity and concentration of blood clotting factors in conventional and virus-inactivated coagulative plasma. Krankenhauspharmazie 9 (1994) 517-522
50. Guide to the preparation, use, and quality assurance of blood components. 9th ed. Strasbourg: Council of Europe Publishing; 2004.